Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol by Fujiyama, S et al.
Phase I clinical study of a novel lipophilic platinum complex
(SM-11355) in patients with hepatocellular carcinoma
refractory to cisplatin/lipiodol
S Fujiyama*,1, J Shibata
1, S Maeda
1, M Tanaka
1, S Noumaru
1, K Sato
1 and K Tomita
1
1Third Department of Internal Medicine, Kumamoto University School of Medicine, Japan
SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC). It is administered via the hepatic artery, using a
carrier, lipiodol, that consists of ethyl esters of iodized poppy seed oil. We have performed a phase I clinical trial of an SM-11355-
lipiodol formulation in 11 HCC patients, in order to investigate the maximum allowable dose and to maximize the efficacy and safety
of the drug in the treatment of HCC. The SM-11355 arterial infusion suspension was administered at doses of 6, 12 and 20mgml
 1
in a maximum lipiodol volume of 6ml. An antitumour efficacy rating of complete response was achieved for one patient and a partial
response rating was achieved for a second patient, giving an overall response rate of 18.2%. Anorexia, nausea and vomiting, pyrexia,
thrombocytopenia and increases in AST, ALT and total bilirubin were observed as adverse effects, but each was transient and each
patient had recovered completely by 4 weeks after drug administration. Hence, we concluded that the maximum allowable dose was
not reached in this study. Overall, our results suggest that SM-11355 is effective in treating HCC and we suggest that the dose for
early phase II trials should be 20mgml
 1.
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It is widely known that lipiodol, which consists of ethyl esters of
iodized poppy seed oil, selectively resides at tumour sites for a long
period of time, following administration via the hepatic artery in
chemoembolisation for hepatocellular carcinoma (HCC) (Nakaku-
ma et al, 1983; Konno et al, 1984). In Japan, chemoembolisation
for HCC is mainly used in advanced stage patients who cannot be
treated with transcatheter arterial embolisation (TAE), or whose
hepatic function standby capacity is low. Furthermore, Camma
et al (2002) have reported that chemoembolisation has a
significant therapeutic benefit, compared with more conservative
therapies, based on the data from 18 radiotherapy centres. Several
attempts have been made to take advantage of the properties of
lipiodol, by coinfusion of lipiodol and anticancer agents such as
zinostatin stimalamer (SMANCS
s), doxorubicin, epirubicin,
mitomycin C and cisplatin (Konno et al, 1983; Kanematsu et al,
1984; Ohishi et al, 1985; Yamashita et al, 1985; Kobayashi et al,
1986; Fukushima et al, 1988; Shibata et al, 1989). However,
although this approach has played an important role in the
treatment of HCC, the efficacy of formulations based on lipiodol
extracts has not been optimized, partly because of incompatibil-
ities of standard antitumour agents with lipiodol.
SM-11355, cis-[((1R,2R)-1,2-cyclohexanediamine-N,N0)bis(myr-
istato)]platinum (II), is a platinum complex (Figure 1) and a novel
therapeutic agent for the treatment of HCC. It is administered via
the hepatic artery, using lipiodol as a carrier (Maeda et al, 1986;
Kishimoto et al, 2000a,b; Shimakura et al, 2002). SM-11355 is a
derivative of cisplatin that acts as a prodrug, through the sustained
release of the predicted active forms of the drug, cyclohexan-1,2-
diamineplatinum (II) dichloride (DPC) and cyclohexan-1,2-diami-
neplatinum (II) dioxide (DPI). SM-11355 demonstrates excellent
compatibility with lipiodol in forming a suspension and, when
suspended in lipiodol, DPC and DPI are released into the aqueous
phase, thus providing the antitumour effect (Maeda et al, 1986;
Kishimoto et al, 1992). Here we report a phase I study that was
conducted to determine the maximum allowable dose of SM-11355
and to examine the pharmacokinetics, efficacy and safety of the
SM-11355 suspension in lipiodol.
MATERIALS AND METHODS
Patient selection
HCC patients were considered eligible for the study if
they possessed the following characteristics: 20–75 years of age;
at least one measurable tumour blush on angiography; no other
therapeutic treatment was effective or suitable; an Eastern
Cooperative Oncology Group (Oken et al, 1982) performance
status of 0–2; adequate hepatic function (aspartate aminotransfer-
ase (AST) and alanine aminotransferase (ALT)p200Ul
 1, total
bilirubinp3.0mgdl
 1); adequate haematological function (white
blood cells (WBCs)X3000mm
 3, plateletsX50000mm
 3,
haemoglobinX10gdl
 1); and adequate renal function (serum
creatininep1.2mgdl
 1). All the HCC cases were recurrences with
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la history of cisplatin–lipiodol therapy. Patients who were not
expected to survive at least 2 months were ineligible. Patients with
active double cancers, who pronounced arteriovenous shunts or
extensive extrahepatic metastasis, were also ineligible. Written
informed consent was obtained from each patient and the study
protocol conformed to the ethical guidance of the 1975 Declaration
of Helsinki.
Investigational agent
SM-11355 was obtained as a lyophilized product containing 20mg
of SM-11355 per vial, and it was stored in the dark under
refrigeration below 51C. Lipiodol, the SM-11355 carrier, contained
10ml of ethyl esters of iodised poppy seed oil fatty acids per
ampule, and was stored in the dark at room temperature. The SM-
11355 arterial infusion suspension was prepared by suspending
SM-11355 in lipiodol at the required concentrations.
Method of administration
The SM-11355–lipiodol suspension was administered via intra-
arterial infusion, using a catheter that was inserted into the
nutrient vessels of the tumour under X-ray fluoroscopy. Admin-
istration continued until the suspension filled the tumour vessels,
with a maximum dosing volume of 6ml.
Choice of dosage and maximum volume
When the SM-11355–lipiodol suspension was administered at a
concentration of 6mgml
 1 and a volume of 0.2mlkg
 1 as a
hepatic arterial infusion to dogs, the toxic low dose was estimated
to be 1.2mgkg
 1 or higher. In humans, this is equivalent to the
administration of 10ml of SM-11355–lipiodol suspension at a
concentration of 6mgml
 1. Based on these results, the starting
concentration of SM-11355 in the phase I clinical study was chosen
to be 6mgml
 1. To determine an appropriate dosing volume, we
considered the intra-arterial infusion of SMANCS
s, a product
similar to SM-11355. SMANCS
s is administered suspended in
SMANCS
s infusion suspension carrier, a product equivalent to
lipiodol, at a maximum volume of 6ml. Lipiodol administration
into the hepatic artery at a volume of 6ml was confirmed to be safe
prior to the study. The safety and efficacy of the SM-11355–
lipiodol suspension mainly depends on the concentration, and the
current study was designed to estimate a maximum allowable dose
of SM-11355 through variation of the concentration. In doing so,
we did not want to alter the volume, other than for reasons of
tumour size, and a volume of 6ml was chosen as the maximum
volume from safety considerations. Up to this limit, the dose
volume of the SM-11355 arterial infusion suspension was varied as
necessary, based on tumour size.
Three dosage groups were used, at concentrations of 6, 12 and
20mgml
 1, and at least three patients were enrolled in each group.
The doses were chosen based on a modified Fibonacci method.
The maximum allowable dose was defined as the minimum dose at
which two out of three or more of the patients experienced adverse
effects of grade X2 in parenchymal organs (i.e., heart, liver,
kidney, blood and lungs), according to the Japanese Society of
Clinical Oncology Adverse Effects Form (Furue et al, 1986).
Principally, SM-11355 was administered as a single intra-arterial
infusion, but additional doses were permitted if the patient
requested continued administration.
Concomitant therapy
Concomitant treatment that might have affected the evaluation of
the effects of SM-11355, such as the use of other anticancer drugs,
radiation therapy, hormone therapy, etc., was not permitted.
However, treatment for the purpose of alleviating symptoms
resulting from adverse reactions occurring during the study was
permitted at the discretion of the investigators.
Measured parameters and time schedules
The background information of the patients was surveyed prior to
the start of administration. Clinical laboratory tests were
conducted prior to the administration and on days 1, 3, 7, 14, 21
and 28 after administration. In these tests, the following
parameters were examined: general haematology (red blood cells
(RBCs), haemoglobin, haematocrit, WBC, platelet count and
differential WBC); serum biochemistry (total protein, albumin,
total bilirubin, AST, ALT, lactic dehydrogenase (LDH), alkaline
phosphatase (ALP), leucine aminopeptidase (LAP), g-glutamyl
transpeptidase (g-GTP), total cholesterol, triglycerides, blood urea
nitrogen (BUN), creatinine, electrolytes (Na
þ,K
þ,C l
 ,C a
2þ),
amylase, P-amylase, lipase, C-reactive protein (CRP), blood
glucose, prothrombin time (PT) and hepaplastin test (HPT));
urinalysis (protein, glucose, urobilinogen, creatinine and N-acetyl-
b-D-glucosaminidase (NAG)); tumour markers (a-fetoprotein
(AFP) and des-g-carboxy prothrombin (DCP)) and electrocardio-
graphy. An evaluation of toxicities relating to adverse effects and
clinical laboratory tests was made in accordance with the Adverse
Effect Form of the Japanese Society of Clinical Oncology (Furue
et al, 1986).
Evaluation of antitumour effect
Antitumour response was evaluated from a computed tomography
(CT) scan examined in the 2 weeks before administration and 1
week, 5 weeks and 3 months after administration. Evaluation was
performed in accordance with the ‘Criteria for the Evaluation of
Direct Efficacy in Treatment of Hepatocellular Carcinoma’ (Liver
Cancer Study Group of Japan, 1994). Tumour size was measured as
the sum of the products of the longest perpendicular diameters of
all measurable lesions. Complete response (CR) was defined as
disappearance or 100% necrosis of all tumours, partial response
(PR) was defined as X50% reduction and/or X50% necrosis and
minor responses (MR) was defined as 25 to 50% reduction and/or
25 to 50% necrosis. Progressive disease (PD) was defined as X25%
enlargement of the tumour. No change (NC) was considered as
disease not qualifying for classification as CR, PR, MR, or PD. We
regarded lipiodol accumulation in tumours as being an indication
of necrosis. The effect of a drug on HCC is often evaluated by
tumour necrosis, and the criteria referred to above include effects
on tumour reduction and necrosis. In addition, Okusaka et al
(2000) have reported that necrotic findings in CT have a
correlation with necrosis determined histopathologically.
Pharmacokinetics
The total platinum concentration in the plasma was measured in at
least two patients in each dosage group before administration and
at 1, 3, 5 and 24h, 3 days, 1 and 3 weeks, and 3, 6, 9 and 12 months
after administration.
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Figure 1 Molecular structure of SM-11355.
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lDiscontinuation of treatment
Administration was discontinued if the patients or their legally
authorised representatives requested discontinuation, or if the
investigator deemed it necessary to discontinue administration
due to serious adverse effects or progression of the disease.
RESULTS
Patient characteristics
The study was conducted from November 1994 to June 1995 at the
Third Department of Internal Medicine, Kumamoto University
Hospital. In all, 11 patients were originally enrolled into the study,
but a grade 3 thrombocytopenia (grade 2 prior to administration)
developed in one patient in the 20mgml
 1 dosage group, and a
further examination of the safety and efficacy was performed to
complete the enrollment. Table 1 lists the demography of the
patients. We note that all the patients had a history of cisplatin–
lipiodol treatment and in seven of the 11 patients this treatment
had been ineffective (Table 2).
The 11 patients received SM-11355 at one of the following doses:
three patients at 6mgml
 1 (dose level 1), three patients at
12mgml
 1 (dose level 2) and five patients at 20mgml
 1 (dose
level 3). All the patients were considered eligible for evaluation of
toxicity and antitumour response. Complete response occurred in
one patient (case No. 6) in the 12mgml
 1 dosage group, and, at
the request of this subject, a second dose was administered, in
accordance with the protocol. At that point in time, a study was
underway concerning the safety of the 20mgml
 1 dose, and the
concentration used in the second dose was 20mgml
 1. The
response of each patient is shown in Table 2, and compared with
the efficacy of the previous cisplatin/lipiodol treatment.
Toxicity
The major haematological toxicity was thrombocytopenia, which
occurred in three of 11 patients, but no decreases in WBCs or
haemoglobin were noted. At dose level 3, grade 3 (preadministra-
tion value: grade 2) and grade 2 (preadministration value: grade 1)
thrombocytopenia were observed in two patients. In addition,
there were four patients with a decrease in lymphocytes, four
patients with an increase in eosinophils, one patient with an
increase in basophils, one patient with a decrease in RBCs and one
patient with a low haematocrit level (Table 3). For patient No. 6, a
Table 1 Characteristics of patients
Number of patients
Item Value or description Total 6mgml
 1 12mgml
 1 20mgml
 1
Evaluable for efficacy 11 3 3 5
Sex Male/female 6/5 0/3 3/0 3/2
Age
a 53–60 1 0 0 1
61–70 7 3 3 1
71–73 3 0 0 3
Tumour site
b PAMLC 1 1 0 0
PAML 3 1 2 0
PAM : AML 1:1 0 0 1:1
AL:PL 2:1 0:1 0 2:0
P2 0 1 1
No. of tumours Single 1 0 0 1
2–3 5 1 1 3
4–10 4 1 2 1
10 or more 1 1 0 0
Tumour size (maximum diameter, mm) p30 1 0 0 1
31–40 4 0 1 3
41–50 3 1 1 1
51–60 1 0 1 0
X61 2 2 0 0
Vascular infiltration Vp0Vv0B0 30 0 3
Vp1Vv0B0 83 3 2
Metastasis No/yes 11/0 3/0 3/0 5/0
TNM stage T2N0M0 10 0 1
T3N0M0 10 1 0
T4N0M0 93 2 4
Stage II 1 0 0 1
III 1 0 1 0
IV-A 9 3 2 4
Cirrhosis No/yes 1/10 0/3 0/3 1/4
c
Type B/type C/type B+type C 1/8/1 0/2/1 1/2/0 0/4/0
Clinical stage I/II/III 5/5/1 0/3/0 2/1/0 3/1/1
Child classification A/B/C 2/5/4 0/1/2 1/1/1 1/3/1
Oesophageal varices No/yes/unknown 4/6/1 1/2/0 1/2/0 2/2/1
Previous history No/yes 1/10 0/3 0/3 1/4
Complications No/yes 0/11 0/3 0/3 0/5
Previous therapy
d No/yes 0/11 0/3 0/3 0/5
Initial/recurrence Initial/recurrent 0/11 0/3 0/3 0/5
AFP (ngml
 1) 100 or more/less than 100 7/4 3/0 1/2 3/2
DCP (AUml
 1) 0.1 or more/less than 0.1 6/5 3/0 1/2 2/3
aThe average age of all patients was 66.8 years and the average ages were 68.3, 65.3 and 66.8 years in the 6, 12 and 20mgml
 1 groups.
bP¼posterior segment; A¼anterior
segment; M¼medial segment; L¼lateral segment; C¼caudal segment;
cchronic hepatitis;
dcisplatin–lipiodol therapy.
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ldecrease in lymphocytes and an increase in monocytes were noted
following the second dose (see above).
Adverse effects observed with relatively high frequency included
anorexia (six out of 11 patients, 55%), nausea and vomiting (seven
out of 11, 64%) and pyrexia (11 out of 11, 100%). However, only
one patient with anorexia and two patients with nausea and
vomiting developed grade 3 symptoms. After the second dose,
patient No. 6 experienced grade 2 pyrexia (Table 4). The
nonhaematological laboratory test abnormalities consisted mainly
of increases in total bilirubin, AST and ALT, which occurred in
four patients (Table 5). All patients had recovered completely from
these effects by 4 weeks after administration.
Response
Of the 11 patients, CR was observed in one patient, PR was
observed in one patient, NC was observed in four patients and PD
was observed in five patients. The overall response rate ((CRþPR/
total number of subjects) 100) was 18.2% (two out of 11). The
response rates by dose levels are shown in Table 6. For example,
CR was observed in one of three patients at dose level 2 (33.3%),
and PR was seen in one of five patients at dose level 3 (20%). For
the CR patient at dose level 2, a second administration at
20mgml
 1 was given, at the request of the patient and in
accordance with the protocol.
Pharmacokinetics
Figure 2 shows the changes in platinum concentration in the
plasma, measured in nine of the 11 patients. No clear relationship
was found between the plasma platinum concentration and the
total dose of SM-11355. The pharmacokinetic parameters were
determined as follows: Cmax 5.3–14.2ngml
 1, Tmax 7–183 days
and t1/2 18.4–707.2 days.
Table 2 Comparison of the effects of SM-11355 treatment and previous
cisplatin/lipiodol treatment
Patient no.
Effect of
cisplatin/lipiodol
SM-11355 dose
(mgml
 1)
Effect of
SM-11355
1 Ineffective 6 PD
2 Ineffective 6 PD
3 Effective 6 PD
4 Ineffective 12 PD
5 Ineffective 12 NC
6 Effective 12 CR
7 Ineffective 20 NC
8 Ineffective 20 PD
9 Effective 20 NC
10 Ineffective 20 PR
11 Unknown 20 NC
Table 3 Haematological toxicities
a
Leucocytopenia (no. of cases) Anaemia
b (no. of cases) Thrombocytopenia (no. of cases)
Grade
c Grade
c Grade
c
Dose (mgml
 1) No. of cases 1 2 3 4 Total (%) 1 2 3 4 Total (%) 1 2 3 4 Total (%)
6 3 0000 0 0 0 0 0 0 1 0 0 0 1
(0) (0) (33.3)
1 2 3 0000 0 0 0 0 0 0 0 0 0 0 0
(0) (0) (0)
2 0 5 0000 0 0 0 0 0 0 0 1 1 0 2
(0) (0) (40.0)
Total 11 0000 0 0 0 0 0 0 1 1 1 0 3
(0) (0) (27.3)
aOther haematological adverse effect: four cases of decreased lymphocyte count, four cases of increased eosinophil count, one case of increased basophile count, one case of
decreased RBC count, one case of decreased haematocrit. Case no. 6, second dose: decreased lymphocyte count, increased monocyte count.
bAnaemia: decreased
haemoglobin.
cSeverity of adverse effects based on Furue et al (1986).
Table 4 Nonhaematological toxicities (signs and symptoms)
a
Anorexia (no. of cases) Nausea/vomiting (no. of cases) Pyrexia (no. of cases)
Grade
b Grade
b Grade
b
Dose (mgml
 1) No. of cases 1 2 3 Total (%) 1 2 3 Total (%) 1 2 3 Total (%)
6 3 1 1 0 2 020 2 0 3 0 3
(66.7) (66.7) (100)
1 2 3 2 0 0 2 020 2 1 2 0 3
(66.7) (66.7) (100)
2 0 5 0 1 1 2 012 3 0 5 0 5
(40.0) (60.0) (100)
Total 11 3 2 1 6 0 5 2 7 1 10 0 11
(54.5) (63.6) (100)
aOther nonhaematological adverse effects: one case of a cough (dose level: 6mgml
 1). Case no. 6, second dose: pyrexia (grade 2).
bSeverity of adverse effects based on Furue
et al (1986).
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lDISCUSSION
In trans-arterial infusion therapy in HCC, doxorubicin hydro-
chloride, epirubicin hydrochloride, mitomycin C, cisplatin and
SMANCS
s have been used as anticancer agents using lipiodol as a
carrier. It is particularly noteworthy that, with the exception of
SMANCS
s, all these agents are used as water-based preparations.
It is difficult to prepare them as a suspension in lipiodol, which is
an oil-based agent, and, at present, therapies involving lipiodol are
clinically used by employing various homemade mixtures and
suspensions. In contrast, SM-11355 was developed specifically to
be used in a lipiodol suspension. This suspension has the unique
characteristics of tumour selectivity and continuous release of
active molecules, and it is expected to demonstrate better
antitumour effects and improved safety, compared to formulations
that are currently used.
We conducted a phase I trial for the purpose of estimating the
maximum allowable dose in trans-arterial infusion of an SM-
11355–lipiodol suspension, and to investigate the safety and
efficacy in the treatment of HCC. Anorexia, nausea and vomiting,
and pyrexia frequently emerged as adverse effects in SM-11355
administration at the lowest dose used. However, these are
considered to be reactions that usually accompany hepatic intra-
arterial infusion as a therapeutic modality, and the patients
recovered within approximately 2 weeks following administration.
The reactions were also judged to be less severe than those
experienced with a cisplatin–lipiodol formulation (Shibata et al,
1989). Transient elevations of AST and ALT were also observed
quite frequently, but all cases were complicated by chronic
hepatitis or cirrhosis. Most of the patients had abnormal values
prior to therapy, and these abnormalities may be characteristic of
hepatic intra-arterial infusion. It is also possible that tumour
necrosis may have played a role in the AST elevation. However, the
treatment is given by direct drug injection into the hepatic artery
and AST elevation was also found in patients who did not show
necrosis. Therefore, we concluded that the drug had an effect on
both tumour cells and normal hepatic cells, and hence we
considered this effect to be an adverse reaction. Of those patients
Table 5 Nonhaematological toxicities (clinical laboratory results)
a
AST increase (no. of cases) ALT increases (no. of cases) Elevated t. bil. (no. of cases)
b
Grade
c Grade
c Grade
c
Dose (mgml
 1) No. of cases 1 2 3 4 Total (%) 1 2 3 4 Total (%) 1 2 3 4 Total (%)
6 3 0100 1 0100 1 1000 1
(33.3) (33.3) (33.3)
1 2 3 0000 0 0000 0 1000 1
(0) (0) (33.3)
2 0 5 0300 3 0300 3 2000 2
(60.0) (60.0) (40.0)
Total 11 0 4 0 0 4 0 4 0 0 4 4 0 0 0 4
(36.4) (36.4) (36.4)
aOther nonhaematological adverse effects: one case of decreased urine volume, one case of elevated g-GTP, 10 cases of elevated CRP, four cases of elevated blood glucose,
eight cases of elevated NAG in urine, two cases of a decreased hepaplastin test, two cases of elevated LDH, one case tested positive for glucose in urine, two cases of decreased
serum potassium, one case of decreased prothrombin time, one case of elevated P-amylase, one case of elevated lipase. Case no. 6, second dose: elevated t. bil. (Grade 1),
elevated CRP, elevated blood glucose, elevated NAG in urine, elevated serum potassium, elevated serum chloride, decreased serum calcium.
bt. bil.: total bilirubin increase.
cSeverity of adverse effects based on Furue et al (1986).
Table 6 Antitumour response
Response (no. of patients)
SM-11355 dose (mgml
 1) No. of evaluable patients CR PR MR NC PD CR rate (%) CR+PR rate (%)
63 0 0 0 0 3 0 0
12 3 1 0 0 1 1 33.3 33.3
20 5 0 1 0 3 1 0 20.0
Total 11 1 1 0 4 5 9.1 18.2
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Figure 2 Change in plasma concentration of total platinum before and
after SM-11355 injection. Measurements of plasma platinum concentration
were taken before SM-11355 administration and at 1, 3, 5 and 24h, 3 days,
1 and 3 weeks, and 3, 6, 9 and 12 months after administration. Three
different doses were administered. Three patients (cases 1, 2 and 3)
received SM-11355 at 6mgml
 1 (dose level 1), three patients (cases 4, 5
and 6) received SM-11355 at 12mgml
 1 (dose level 2) and five patients
(cases 7, 8, 9, 10 and 11) received SM-11355 at 20mgml
 1 (dose level 3).
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 1, one had grade 3 (preadministration
value: grade 2) thrombocytopenia and one had grade 2 (pre-
administration value: grade 1) thrombocytopenia, based on the
scale of Furue et al (1986). There were no other clinically
significant adverse effects, and the adverse effects associated with
SM-11355 were considered mild for an anticancer agent.
At a dose of 20mgml
 1, adverse effects of grade 2 or higher
were noted in three of five patients. With the exception of one
patient with increased AST, all were one-grade fluctuations from
preadministration grades, and we concluded that the maximum
allowable dose had not been reached at a concentration of
20mgml
 1. Since the maximum possible concentration that can be
used for this preparation is 20mgml
 1, we concluded that the
recommended dose for use in early phase II clinical trials of SM-
11355 should be 20mgml
 1.
Plasma platinum concentrations were measured in nine of the
11 patients. No clear dose dependency was observed between the
plasma platinum concentration and either the dosing concentra-
tion or total dose. The pharmacokinetic parameters of SM-11355
(Cmax 5.3–14.2ngml
 1, Tmax 7–183 days and t1/2 18.4–707.2 days)
suggest that, in comparison with cisplatin–lipiodol (Cmax 2–
3mgml
 1, t1/2 5–7 days) (Shibata et al, 1989), the plasma platinum
concentration of SM-11355 is considerably lower (approximately
1/100–1/500 than that of cisplatin), but the half-life is much
longer. We believe that this reflects the sustained release properties
of the SM-11355–lipiodol formulation, in which SM-11355
migrates slowly from the lipiodol phase to the aqueous phase. In
two patients receiving a dose of 20mgml
 1, the lipiodol was
washed out earlier than expected, and the retention rate at 3
months after administration was insufficient. However, tumour
shrinkage was sustained for 3 months in these patients, although
the tumour was not completely eliminated. Again, this probably
reflects the ability of SM-11355 to exhibit sustained efficacy.
Finally, the antitumour response of one patient out of 11 was
rated as CR at a dose of 12mgml
 1 and one patient rated PR at a
dose of 20mgml
 1, for an overall response rate of 18.2%. In
interpreting these statistics, it is important to note that patients
treated at a low dose level were included, because this is a phase I
trial. Furthermore, most of the patients had recurrent, advanced
disease, with a history of largely unsuccessful cisplatin–lipiodol
therapy. Hence, against this background, our results suggest that
SM-11355 in conjunction with a lipiodol carrier shows excellent
promise for the treatment of HCC. It is, however, recognised that
this conclusion is based on data from a phase I study, and further
studies will be needed to confirm the efficacy of SM-11355 for
HCC.
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